Table 2.

Genotype distribution of the single-nucleotide polymorphism rs3814113 by affection status for ovarian cancer and associations with ovarian cancer risk^*

Gene	rs3814113 genotype	Unaffected status, No. (%)	Affected status, No. (%)	HR (95% CI)	P†
No censoring at breast cancer
BRCA1	TT	3526 (43.3)	950 (50.3)	1 (ref)
	CT	3671 (45.1)	775 (41.1)	0.79 (0.71 to 0.88)
	CC	945 (11.6)	162 (8.6)	0.61 (0.51 to 0.74)
	2 df test				3.9 × 10−8
	Per-allele analysis			0.78 (0.72 to 0.85)	4.8 × 10−9
BRCA2	TT	2436 (45.8)	269 (51.4)	1 (ref)
	CT	2288 (43.1)	216 (41.3)	0.82 (0.67 to 1.00)
	CC	590 (11.1)	38 (7.3)	0.56 (0.39 to 0.80)
	2 df test				.0027
	Per-allele analysis			0.78 (0.67 to 0.90)	.00055
BRCA1/2 combined	TT	5962 (44.3)	1219 (50.6)	1 (ref)
	CT	5959 (44.3)	991 (41.1)	0.80 (0.73 to 0.89)
	CC	1535 (11.4)	200 (8.3)	0.60 (0.51 to 0.71)
	2 df test				2.2 × 10−10
	Per-allele analysis			0.79 (0.73 to 0.84)	2.0 × 10−11
With censoring at breast cancer
BRCA1	TT	3777 (43.6)	699 (51.3)	1 (ref)
	CT	3891 (44.9)	555 (40.7)	0.79 (0.68 to 0.92)
	CC	998 (11.5)	109 (8.0)	0.59 (0.44 to 0.77)
	2 df test				6.7 × 10−5
	Per-allele analysis			0.77 (0.69 to 0.87)	1.0 × 10−5
BRCA2	TT	2514 (46.0)	191 (50.4)	1 (ref)
	CT	2345 (43.0)	159 (42.0)	0.86 (0.65 to 1.12)
	CC	599 (11.0)	29 (7.6)	0.62 (0.39 to 1.01)
	2 df test				.12
	Per-allele analysis			0.82 (0.67 to 0.99)	.042
BRCA1/2 combined	TT	6291 (44.5)	890 (51.1)	1 (ref)
	CT	6236 (44.2)	714 (41.0)	0.81 (0.73 to 0.91)
	CC	1597 (11.3)	138 (7.9)	0.60 (0.49 to 0.73)
	2 df test				1.6 × 10−7
	Per-allele analysis			0.79 (0.73 to 0.86)	1.9 × 10−8

^*CI = confidence interval; HR = hazard ratio; ref = referent.

^†A robust Wald test statistic was used. All statistical tests were two-sided.